A French biotech had developed a live biotherapeutic product to target obesity and metabolic disease but were hindered by blocking points in the product development process. We worked alongside the Client to identify the specific regulatory and scientific gaps in their plan. This critical information helped to form the solid foundation of their regulatory strategy and nonclinical development plan.
Resources
blog
Introduction Bacterial vaginosis (BV) BV is a common vaginal condition characterised by odorous grey vaginal discharge which can be really…
webinar
Microbiome science has grown over the past years with high potential to provide innovative, efficient, and targeted solutions to various…
blog
We have seen in the first part of our Phage therapeutics Series that Phages, these viruses that can infect and provoke…
Case study
An APAC-based biotech had developed a live biotherapeutic product to target a rare liver disease with a high unmet medical…
